RxDoctor Payments Data

Anthony Inzana

Physician Assistant · Rochester, NYNPI 1164468872

Payments from drug & device makers

$22,262in general payments, 2019–2025

Across 722 payments — averaging $30.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$3K
  • EMD Serono, Inc.$2K
  • Livanova USA, Inc.$2K
  • AbbVie$2K
  • Biogen$1K
  • Abbott$1K
  • plus $12K from 48 others

What the payments were for

  • Consulting fees$7503%
  • Speaking & faculty fees$1,2606%
  • Travel & lodging$1,4657%
  • Food & beverage$18,55383%
  • Education$2341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,262 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$16,874
Medicare patients
72
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide14$127,541
CopaxoneGlatiramer Acetate14$78,917
NourianzIstradefylline20$50,443
Teriflunomide37$45,637
Glatiramer Acetate18$43,438
UbrelvyUbrogepant47$43,080
Ajovy AutoinjectorFremanezumab-Vfrm27$29,515
Emgality PenGalcanezumab-Gnlm25$22,203
Nurtec OdtRimegepant Sulfate18$18,619
Aimovig AutoinjectorErenumab-Aooe24$16,861
Trokendi XrTopiramate11$14,592
Sumatriptan Succinate43$10,296
Dalfampridine ErDalfampridine17$9,726
Levetiracetam101$4,575
Carbamazepine19$2,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiAubagio$2,787$127,54114 claims
Teva Pharmaceuticals USA, Inc.Copaxone$542$78,91714 claims
Kyowa Kirin, Inc.Nourianz$357$50,44320 claims
AbbVieUbrelvy$1,742$43,08047 claims
PfizerNurtec Odt$123$18,61918 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$39$14,59211 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$280$1,48417 claims
Upsher-smith Laboratories LLCTopiramate$102$83172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →